VBI Vaccines focuses on leveraging advanced immunological technologies to develop vaccines and immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Their pipeline includes a range of candidates that utilize virus-like particle (VLP) technology, which mimics the structure of viruses to stimulate robust immune responses without containing infectious material. This approach allows for the creation of sub-unit vaccines that can effectively prepare the immune system to combat various pathogens, including hepatitis B, cytomegalovirus, and SARS-CoV-2. VBI's innovative platforms include enveloped VLPs (eVLPs) and mRNA-launched eVLPs (MLE), which enhance the immune response by presenting antigens in a manner that closely resembles natural viral infections.

The eVLP technology provides a stable core and lipid bilayer, facilitating the presentation of antigens to the immune system, while the MLE platform combines the advantages of mRNA technology with VLPs, enabling cells to produce eVLPs in vivo. This dual approach not only enhances the generation of neutralizing antibodies but also promotes the activation of T-cell responses, making it a promising strategy for developing effective vaccines. VBI's commitment to addressing significant public health challenges is evident in their focus on creating flexible and customizable vaccine solutions that can adapt to various infectious diseases and cancer types.

United States

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Infectious Diseases

Liver Diseases

VBI Vaccines

Hepatitis B

Hepatitis B vaccine

Pain

This vaccine is a 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use and commercially-available in Israel, under the name Sci-B-Vac®. In December 2017, VBI initiated patient dosing in a global Phase 3 clinical program that consisted of two concurrent pivotal studies: PROTECT, a safety and immunogenicity study, and CONSTANT, a lot-to-lot consistency study. Data from both the PROTECT study and the CONSTANT study, which were announced in June 2019 and January 2020, respectively, comprise the basis for the regulatory submissions in the U.S., Europe, and Canada.

PreHevbrio (Sci-B-Vac®)

Chronic hepatitis B

VBI believes VBI-2601 has the unique potential to do this by targeting B- and T-cell immunity through several key mechanisms of action, including neutralizing circulation of the hepatitis B virus, blocking infection of hepatocytes via Pre-S1 immunity, and enabling immune-mediated clearance of HBV-infected hepatocytes (<a href="https://www.vbivaccines.com/hbv/#:~:text=VBI%20believes%20VBI%2D2601%20has,clearance%20of%20HBV%2Dinfected%20hepatocytes.">Learn more HERE</a>).

VBI-2601 (BRII-179) combo w/ PEG-IFNα 

Cancer

Glioblastoma

VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM).&nbsp;

VBI-1901 (eVLP)

COVID-19

VBI-2900 consists of two enveloped virus-like particle (eVLP) vaccine candidates: (1) VBI-2901, a trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins, and (2) VBI-2902, a monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein. The vaccine program was developed in collaboration with the National Research Council (NRC) beginning in early 2020, with promising preclinical data announced August 2020 enabling the selection of the two clinical candidates. Through their Strategic Innovation Fund, the Government of Canada has awarded VBI up to CAD$56 million to support clinical development through Phase 2 studies, to be paid as retrospective reimbursement for eligible expenses incurred.

VBI-2905

VBI-2901

VBI-2902

Cytomegalovirus

Our prophylactic CMVvaccine candidate uses the eVLP platformto express a modified formof the CMVglycoprotein B antigen and is adjuvanted with alum, an adjuvant used in FDA-approved products.

VBI Vaccines

Company Details